Emergency surgery in the era of molecular treatment of solid tumours

被引：30
作者：
Rutkowski, Piotr [1 ]
Ruka, Wlodzimierz [1 ]
机构：
[1] M Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, PL-02781 Warsaw, Poland
来源：
LANCET ONCOLOGY | 2009年 / 10卷 / 02期
关键词：
GASTROINTESTINAL STROMAL TUMORS; METASTATIC COLORECTAL-CANCER; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; PHASE-II TRIAL; IMATINIB MESYLATE; SURGICAL-MANAGEMENT; TARGETED THERAPIES; DOSE IMATINIB;
D O I：
10.1016/S1470-2045(09)70017-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In the advancing era of molecular therapy of solid tumours, emergency treatment of complications, such as bowel perforation, haemorrhage, and tumour rupture, is likely to evolve into one of the main challenges of surgical oncology. These complications might be caused by disease progression from resistance to therapy, side-effects of therapy on normal vasculature, and therapeutic induction of excessively responding tumours. This Review outlines the probability and management of emergency operations during molecularly targeted therapy of solid tumours. Special attention is given to advanced gastrointestinal stromal tumours and colorectal cancer, and therapy with imatinib, sunitinib, and bevacizumab.
引用
收藏
页码：157 / 163
页数：7
相关论文
共 67 条
  • [1] Surgical resection of gastrointestinal stromal tumors after treatment with imatinib
    Andtbacka, Robert H. I.
    Ng, Chaan S.
    Scaife, Courtney L.
    Cormier, Janice N.
    Hunt, Kelly K.
    Pisters, Peter W. T.
    Pollock, Raphael E.
    Benjamin, Robert S.
    Burgess, Michael A.
    Chen, Lei L.
    Trent, Jonathan
    Patel, Shreyaskumar R.
    Raymond, Kevin
    Feig, Barry W.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (01) : 14 - 24
  • [2] Management of bevacizumab-associated bowel perforation: a case series and review of the literature
    Badgwell, B. D.
    Camp, E. R.
    Feig, B.
    Wolff, R. A.
    Eng, C.
    Ellis, L. M.
    Cormier, J. N.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (03) : 577 - 582
  • [3] Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib
    Bauer, S
    Hartmann, JT
    de Wit, M
    Lang, H
    Grabellus, F
    Antoch, G
    Niebel, W
    Erhard, J
    Ebeling, P
    Zeth, M
    Taeger, G
    Seeber, S
    Flasshove, M
    Schütte, J
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (02) : 316 - 325
  • [4] BERRY S, 2005, P AM SOC CLIN ONC GA
  • [5] Targeted therapies in lung cancer
    Besse, B.
    Ropert, S.
    Soria, J. C.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 135 - 142
  • [6] Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Blanke, Charles D.
    Demetri, George D.
    von Mehren, Margaret
    Heinrich, Michael C.
    Eisenberg, Burton
    Fletcher, Jonathan A.
    Corless, Christopher L.
    Fletcher, Christopher D. M.
    Roberts, Peter J.
    Heinz, Daniela
    Wehre, Elisabeth
    Nikolova, Zariana
    Joensuu, Heikki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 620 - 625
  • [7] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Blanke, Charles D.
    Rankin, Cathryn
    Demetri, George D.
    Ryan, Christopher W.
    von Mehren, Margaret
    Benjamin, Robert S.
    Raymond, A. Kevin
    Bramwell, Vivien H. C.
    Baker, Laurence H.
    Maki, Robert G.
    Tanaka, Michael
    Hecht, J. Randolph
    Heinrich, Michael C.
    Fletcher, Christopher D. M.
    Crowley, John J.
    Borden, Ernest C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 626 - 632
  • [8] Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era
    Bonvalot, S.
    Eldweny, H.
    Le Pechoux, C.
    Vanel, D.
    Terrier, P.
    Cavalcanti, A.
    Robert, C.
    Lassau, N.
    Le Cesne, A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (12) : 1596 - 1603
  • [9] CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings
    Choi, H
    Charnsangavej, C
    Faria, SD
    Tamm, EP
    Benjamin, RS
    Johnson, MM
    Macapinlac, HA
    Podoloff, DA
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2004, 183 (06) : 1619 - 1628
  • [10] Biology of gastrointestinal stromal tumors
    Corless, CL
    Fletcher, JA
    Heinrich, MC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3813 - 3825
1234567